Strategic partnerships Waters has active collaboration activity with peer organizations and CROs, including a Canadian strategic partnership with CellCarta for companion diagnostics and next-generation flow cytometry opportunities, plus at-home HPV screening collaboration with LetsGetChecked. Leverage these partnership channels to propose integrated analytical workflows, larger lab deployment deals, or joint solutions for pharma/biotech customers.

Global launches Waters regularly expands its product portfolio with global launches such as the BD FACSDiscover A7 Cell Analyzer. This indicates continued demand for advanced analytical instruments and new sale opportunities across life sciences and diagnostics segments, especially in labs upgrading cytometry capabilities.

Strategic markets Market activity includes leadership appointments and regional communications expansion in India, signaling emphasis on regional growth and GCC optimization. This creates entry points for localized sales efforts, service contracts, and training packages tailored to high-growth markets.

Financial health With a market cap around $43.6B and a revenue range in the tens of millions, Waters demonstrates strong brand presence and financial stability that can support larger, multi-year instruments and software deals, as well as bundled service and maintenance offerings.

End-to-end solutions Waters operates across analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. This breadth enables cross-sell across product lines such as instrument platforms, software analytics, and lab workflow optimization, creating bundled selling opportunities for customers pursuing end-to-end solutions.